First implant of InControl's Metrix 3020:
This article was originally published in Clinica
Executive Summary
InControl's Metrix 3020 atrial defibrillator has been implanted for the first time at the Universitair Ziekenhuis Ghent in Belgium. The defibrillator incorporates a waveform which allows the delivery of up to six Joules of energy as compared with three Joules for the company's Metrix 3000 defibrillator. The Metrix 3020 is approved for clinical investigation in Belgium but is awaiting regulatory clearance in other European countries and the US (see Clinica No 699, p 18).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.